Safety and Efficacy of Pucotenlimab in pLECC

PHASE2RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

December 30, 2027

Study Completion Date

December 30, 2028

Conditions
Lymphoepithelioma-like CarcinomaLymphoepitheliomaCarcinoma
Interventions
DRUG

Pucotenlimab combined with GP regimen

A total of 33 cases are planned to be enrolled. All the subjects will receive Pucotenlimab (3mg/kg, on day 1, with a maximum dose not exceeding 200mg), administered once every 3 weeks (Q3W), and combined with the GP regimen. The chemotherapy is a fixed regimen, with Gemcitabine at a dose of 1g/m² on day 1 and day 8, and cisplatin at a dose of 80mg/m² on day 1. The chemotherapy will be given for 3 to 6 cycles, once every 3 weeks (Q3W).

Trial Locations (1)

510060

RECRUITING

Yizhuo Zhang, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER